1. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo;O'Farrell;Blood,2003
2. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients;O'Farrell;Clin. Cancer Res.,2003
3. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models;Schueneman;Cancer Res.,2003
4. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with ‘standard of care’ therapeutic agents for the treatment of breast cancer;Abrams;Mol. Cancer Ther.,2003
5. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship;Mendel;Clin. Cancer Res.,2003